• Towa Pharmaceutical's April-September 2026 net income attributable to shareholders fell 16% year over year to JPY 6.87 billion.
• Sales rose 9% to JPY 142.25 billion, while operating profit climbed 22% to JPY 12.75 billion year over year.
• Higher domestic volumes and prices and stronger European sales supported sales and operating profit growth, offsetting weaker performance at Sansei Pharmaceutical.
• For the year ending March 2027, forecasts remain unchanged at JPY 21.5 billion net income and JPY 304 billion sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOWA Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.